Ultragenyx to Host Conference Call for First Quarter 2025 Financial Results and Corporate Update
Ultragenyx Pharmaceutical (NASDAQ: RARE), a leading biopharmaceutical company specializing in rare and ultra-rare genetic diseases, has scheduled its first quarter 2025 financial results conference call.
The earnings call will take place on Tuesday, May 6, 2025, at 5:00 p.m. ET. During this call, the company will present its financial performance for the quarter ending March 31, 2025, along with a corporate update.
Investors and interested parties can access the live webcast through the company's investor relations website at https://ir.ultragenyx.com/events-presentations. A replay of the conference call will remain available for three months following the presentation.
Ultragenyx Pharmaceutical (NASDAQ: RARE), un'azienda biopharmaceutical leader specializzata in malattie genetiche rare e ultra-rare, ha programmato la conference call per i risultati finanziari del primo trimestre 2025.
La chiamata sugli utili si terrà martedì 6 maggio 2025 alle 17:00 ET. Durante la call, l'azienda presenterà la performance finanziaria del trimestre conclusosi il 31 marzo 2025, insieme a un aggiornamento aziendale.
Investitori e soggetti interessati potranno seguire la diretta streaming tramite il sito web delle relazioni con gli investitori all'indirizzo https://ir.ultragenyx.com/events-presentations. La registrazione della conference call resterà disponibile per tre mesi dopo la presentazione.
Ultragenyx Pharmaceutical (NASDAQ: RARE), una compañía biofarmacéutica líder especializada en enfermedades genéticas raras y ultra-raras, ha programado su conferencia telefónica de resultados financieros del primer trimestre de 2025.
La llamada de resultados se realizará el martes 6 de mayo de 2025 a las 5:00 p.m. ET. Durante esta llamada, la empresa presentará su desempeño financiero correspondiente al trimestre finalizado el 31 de marzo de 2025, junto con una actualización corporativa.
Inversionistas y partes interesadas podrán acceder a la transmisión en vivo a través del sitio web de relaciones con inversionistas de la compañía en https://ir.ultragenyx.com/events-presentations. La grabación de la conferencia estará disponible durante tres meses después de la presentación.
Ultragenyx Pharmaceutical (NASDAQ: RARE)는 희귀 및 초희귀 유전 질환을 전문으로 하는 선도적인 바이오제약 회사로, 2025년 1분기 재무 실적 컨퍼런스 콜을 예정하고 있습니다.
실적 발표 콜은 2025년 5월 6일 화요일 오후 5시(동부시간)에 진행됩니다. 이 콜에서 회사는 2025년 3월 31일 종료된 분기의 재무 성과와 기업 업데이트를 발표할 예정입니다.
투자자 및 관심 있는 분들은 회사 투자자 관계 웹사이트 https://ir.ultragenyx.com/events-presentations를 통해 생중계 웹캐스트에 접속할 수 있습니다. 컨퍼런스 콜 녹음은 발표 후 3개월간 다시보기로 제공됩니다.
Ultragenyx Pharmaceutical (NASDAQ : RARE), une société biopharmaceutique de premier plan spécialisée dans les maladies génétiques rares et ultra-rares, a programmé sa conférence téléphonique sur les résultats financiers du premier trimestre 2025.
L'appel aux résultats aura lieu le mardi 6 mai 2025 à 17h00 ET. Au cours de cet appel, la société présentera ses performances financières pour le trimestre se terminant le 31 mars 2025, ainsi qu'une mise à jour d'entreprise.
Les investisseurs et les parties intéressées peuvent accéder à la diffusion en direct via le site web des relations investisseurs de la société à l'adresse https://ir.ultragenyx.com/events-presentations. La rediffusion de la conférence téléphonique restera disponible pendant trois mois après la présentation.
Ultragenyx Pharmaceutical (NASDAQ: RARE), ein führendes biopharmazeutisches Unternehmen, das sich auf seltene und ultra-seltene genetische Erkrankungen spezialisiert hat, hat seine Telefonkonferenz zu den Finanzergebnissen des ersten Quartals 2025 angesetzt.
Der Ergebnisanruf findet am Dienstag, den 6. Mai 2025, um 17:00 Uhr ET statt. Während dieses Anrufs wird das Unternehmen seine finanzielle Leistung für das Quartal zum 31. März 2025 sowie ein Unternehmensupdate präsentieren.
Investoren und Interessierte können den Live-Webcast über die Investor-Relations-Website des Unternehmens unter https://ir.ultragenyx.com/events-presentations verfolgen. Eine Aufzeichnung der Telefonkonferenz wird für drei Monate nach der Präsentation verfügbar sein.
- None.
- None.
NOVATO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Tuesday, May 6, 2025, to discuss its financial results and corporate update for the quarter ending March 31, 2025.
The live and replayed webcast of the call will be available through the company’s website at https://ir.ultragenyx.com/events-presentations. The replay of the call will be available for three months.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
Contact Ultragenyx
Investors
Joshua Higa
(415) 475-6370
ir@ultragenyx.com
Media
Joey Fleury
(415) 946-1090
media@ultragenyx.com
FAQ
When is Ultragenyx (RARE) Q1 2025 earnings call?
How can I listen to Ultragenyx RARE Q1 2025 earnings call?
How long will Ultragenyx RARE Q1 2025 earnings call replay be available?
What will be discussed in Ultragenyx RARE May 6 earnings call?
What is Ultragenyx RARE's business focus?
